Printed on 3/17/2026
For informational purposes only. This is not medical advice.
The 4T scoring system estimates pretest probability of HIT using four criteria: Thrombocytopenia severity, Timing of platelet fall, Thrombosis or other sequelae, and absence of oTher causes. Low scores (<4) have excellent negative predictive value, reducing unnecessary HIT antibody testing. HIT causes paradoxical thrombosis — assess DVT/PE risk with [Wells DVT Score](/tools/wells-dvt-score) and [Wells PE Score](/tools/wells-pe-score). When transitioning to long-term anticoagulation after HIT resolves, assess stroke risk with [CHA2DS2-VASc](/tools/cha2ds2-vasc) and bleeding risk with [HAS-BLED](/tools/has-bled). Monitor ICU severity with [SOFA Score](/tools/sofa-score).
Formula: Thrombocytopenia (0–2) + Timing (0–2) + Thrombosis (0–2) + Other causes (0–2). Total 0–8.
When a hospitalized patient on heparin (unfractionated or low-molecular-weight) develops new or worsening thrombocytopenia, immediately consider heparin-induced thrombocytopenia (HIT) in the differential diagnosis. HIT is a life-threatening prothrombotic condition caused by antibodies against platelet factor 4 (PF4)-heparin complexes, leading to paradoxical thrombosis despite low platelet counts. The 4T score is the first-line risk stratification tool to determine the pretest probability of HIT before ordering laboratory confirmation. Start by scoring the magnitude of thrombocytopenia (the first 'T'). **2 points:** Platelet fall >50% AND platelet nadir ≥20,000/μL. This is the classic HIT presentation—a 50% or greater drop from baseline but platelets remaining above 20K. **1 point:** Platelet fall 30–50% OR platelet nadir 10,000–19,000/μL. Moderate drop or severe thrombocytopenia. **0 points:** Platelet fall <30% OR platelet nadir <10,000/μL. HIT rarely causes platelets to drop below 10–20K; profound thrombocytopenia suggests alternative etiologies (DIC, sepsis, drug-induced, TTP/HUS). Always compare the current platelet count to the patient's BASELINE (pre-heparin) count, not the hospital admission count. Many patients have mild baseline thrombocytopenia from chronic liver disease, chemotherapy, or immune thrombocytopenia—a 30–50% drop from that baseline is still clinically significant. Document the baseline and current platelet counts clearly when calculating the 4T score.
Score the **Timing** of platelet fall relative to heparin exposure (the second 'T'). **2 points:** Clear onset at days 5–10 after heparin initiation OR ≤1 day if heparin exposure within the past 30 days (indicating rapid-onset HIT from pre-existing antibodies). **1 point:** Consistent with HIT but not entirely clear (e.g., platelet fall after day 10, or timing unclear due to missing baseline counts, or fall ≤1 day with heparin exposure 31–100 days ago). **0 points:** Platelet fall ≤4 days without recent heparin exposure. Classic HIT occurs 5–10 days after starting heparin as antibodies develop; earlier drops suggest alternative causes unless there's recent heparin re-exposure. Score **Thrombosis or other sequelae** (the third 'T'). **2 points:** New thrombosis confirmed by imaging (DVT, PE, arterial thrombosis, limb ischemia), skin necrosis at heparin injection sites, or acute systemic reaction after heparin bolus (fever, chills, dyspnea, hypotension). **1 point:** Progressive or recurrent thrombosis, non-necrotizing skin lesions, or suspected thrombosis not yet proven. **0 points:** No thrombosis or other sequelae. HIT is a prothrombotic state—up to 50% of HIT patients develop thrombosis (HITT = HIT with thrombosis), and it paradoxically occurs despite thrombocytopenia. Finally, score the presence of **oTher causes** for thrombocytopenia (the fourth 'T'). **2 points:** No other apparent cause for thrombocytopenia. **1 point:** Possible other cause is present (e.g., sepsis, recent chemotherapy, concurrent medication). **0 points:** Definite other cause present (e.g., DIC with elevated PT/PTT and low fibrinogen, recent vancomycin with vanc-induced thrombocytopenia). This component requires clinical judgment and a systematic review of alternative etiologies (sepsis, medications, immune causes, bone marrow suppression, consumptive coagulopathy).
Sum all four components to obtain a total score ranging from 0 to 8. Interpret as follows: **0–3 points (LOW probability):** Approximately 5% chance of HIT. The negative predictive value of a low 4T score exceeds 99%, making it an excellent rule-out tool. In low-probability patients, HIT antibody testing is NOT recommended (it yields more false positives than true positives in this population), and heparin can usually be continued or switched to an alternative anticoagulant for other clinical reasons. No empiric treatment for HIT is needed while awaiting test results. **4–5 points (INTERMEDIATE probability):** Approximately 14% chance of HIT. These patients require HIT antibody testing (HIT ELISA detecting anti-PF4/heparin antibodies). While awaiting results (typically 24–48 hours), STOP all heparin (including heparin flushes, heparin-coated catheters) and initiate alternative anticoagulation with a direct thrombin inhibitor (argatroban, bivalirudin) or fondaparinux if the clinical suspicion is moderate to high. Do not start warfarin until platelets recover (warfarin can cause venous limb gangrene in acute HIT). If the ELISA is negative, HIT is excluded and heparin can be resumed. If positive, send confirmatory serotonin release assay (SRA). **6–8 points (HIGH probability):** Approximately 64% chance of HIT. Immediately STOP all heparin products and start alternative anticoagulation (do not wait for lab results, as thrombosis risk is high). Send HIT ELISA and confirmatory SRA. Obtain lower extremity Doppler ultrasound to screen for DVT even if the patient is asymptomatic (many HIT patients have occult thrombosis). Avoid platelet transfusions unless life-threatening bleeding occurs (platelets can paradoxically worsen thrombosis in HIT). Continue alternative anticoagulation until platelets recover to >150,000/μL, then transition to warfarin with 5-day overlap. Document the diagnosis of HIT in the medical record and advise future heparin avoidance (consider medical alert bracelet).
Intensivists, hospitalists, and ICU nurses
Apply the 4T score to every patient on heparin who develops new thrombocytopenia (platelet count drop >30–50% from baseline). In the ICU, thrombocytopenia has many competing causes (sepsis, DIC, dilutional from massive transfusion, drug-induced from vancomycin or linezolid), making the 4T score critical for prioritizing HIT in the differential. A low 4T score (0–3) can avoid unnecessary heparin cessation and expensive alternative anticoagulation (argatroban costs ~$1,000–2,000 per day vs heparin at ~$10 per day), while high scores (6–8) prompt immediate action to prevent life-threatening thrombosis. Use the score to guide daily rounds discussions and document the HIT assessment systematically.
Surgical teams and orthopedic surgeons
Patients undergoing major orthopedic surgery (total hip/knee arthroplasty, spinal surgery) often receive heparin prophylaxis for VTE prevention and are at risk for HIT, especially with prolonged unfractionated heparin exposure. Post-operative thrombocytopenia is common from hemodilution, blood loss, and surgical stress, but a >50% platelet drop 5–10 days post-op with new thrombosis (DVT, PE, limb ischemia) should trigger a 4T score. A high 4T score in a post-op patient requires urgent consultation with hematology and vascular surgery, as HIT-associated arterial thrombosis can lead to limb loss. Use the score to differentiate benign post-op platelet drops from dangerous immune-mediated HIT.
Hematologists and hematology fellows
When consulted for thrombocytopenia in a heparinized patient, calculate the 4T score immediately to stratify pretest probability before ordering HIT antibody panels. A low 4T score (0–3) has a >99% negative predictive value—you can confidently tell the primary team that HIT is very unlikely and avoid unnecessary testing (HIT ELISAs have high false-positive rates, especially in low-probability patients). Intermediate and high scores warrant HIT ELISA and confirmatory serotonin release assay (SRA) or heparin-induced platelet activation (HIPA) assay. Use the 4T score to educate referring teams about HIT diagnosis: it's a clinical-pathologic diagnosis requiring both compatible clinical features (captured by the 4T score) and positive laboratory confirmation. Document the 4T score in your consultation note and update it as clinical features evolve.
Cardiologists, cardiac surgeons, and cardiothoracic ICU staff
Patients undergoing cardiac surgery, coronary angiography, or receiving heparin for acute coronary syndromes, atrial fibrillation, or mechanical circulatory support are at risk for HIT. Cardiac surgery patients may have transient thrombocytopenia from hemodilution, cardiopulmonary bypass, and platelet consumption, making HIT diagnosis challenging. Use the 4T score to assess whether a post-CABG patient's thrombocytopenia is expected (low score, likely dilutional/consumptive) or concerning for HIT (high score, especially if associated with new graft thrombosis, stroke, or limb ischemia). In patients requiring ongoing anticoagulation for mechanical valves or ventricular assist devices (VADs), a high 4T score necessitates transition to bivalirudin or argatroban, which requires careful monitoring and dose adjustment.
Hospital QI teams and pharmacy anticoagulation services
Implement the 4T score as part of an institutional HIT diagnostic pathway to reduce unnecessary HIT antibody testing (which has high false-positive rates and costs ~$200–500 per test) and inappropriate use of expensive alternative anticoagulants. Create a clinical decision support tool in the EHR that auto-calculates the 4T score when a heparinized patient's platelets drop >30%, prompting clinicians to document the score and follow evidence-based pathways: low score → no testing, continue heparin; intermediate/high score → stop heparin, test for HIT, start alternative anticoagulation. Track outcomes: rates of HIT diagnosis, time to heparin cessation, inappropriate ELISA ordering in low-probability patients, and thrombotic complications. Many hospitals have reduced HIT antibody testing by 40–60% after implementing 4T score-based pathways without increasing missed HIT diagnoses.
Medical students, residents, and teaching faculty
Teach the 4T score as the foundational tool for HIT diagnosis, emphasizing that HIT is a clinicopathologic diagnosis requiring BOTH a compatible clinical picture (4T score) AND positive laboratory confirmation. Use the 4T mnemonic (Thrombocytopenia, Timing, Thrombosis, oTher causes) to help learners remember the four components. Quiz residents on common pitfalls: (1) Don't forget to check for heparin flushes and heparin-coated catheters when looking for heparin exposure. (2) HIT rarely causes platelets <10–20K; profound thrombocytopenia suggests other etiologies. (3) 'Timing' includes rapid-onset HIT (platelet drop within 24 hours in patients with heparin exposure in the past 30 days due to circulating antibodies). (4) Always look for occult thrombosis in high-probability HIT—bilateral lower extremity Dopplers should be routine. Use case-based teaching with actual 4T score calculation to reinforce diagnostic reasoning and appropriate testing strategies.
The most clinically valuable aspect of the 4T score is its ability to rule out HIT in low-probability patients. A score of 0–3 indicates <5% HIT prevalence, and the negative predictive value exceeds 99%—meaning you can confidently exclude HIT without laboratory testing. This is critical because HIT ELISA has a high false-positive rate (50–70% of positive ELISAs are false positives), especially in low-probability populations. Ordering HIT testing in low 4T score patients creates more confusion than clarity—a positive ELISA in a low-probability patient leads to unnecessary heparin cessation, expensive alternative anticoagulation, and delays in addressing the true cause of thrombocytopenia (sepsis, medications, immune). ASH guidelines recommend AGAINST routine HIT antibody testing in low-probability (4T ≤3) patients. Use the low 4T score to reassure teams that HIT is very unlikely and redirect diagnostic efforts toward more probable etiologies.
Many clinicians look for obvious heparin exposure (subcutaneous prophylaxis, IV infusion, dialysis) but miss occult sources: heparin flushes for IV catheter patency (common in ICUs and on general floors), heparin-coated central venous catheters, arterial line flushes, and heparin lock solutions. Even these minimal heparin exposures (10–100 units per flush, multiple times daily) can trigger HIT in sensitized patients. When calculating the 'Timing' component of the 4T score, ask specifically: 'Is this patient receiving heparin flushes? Are any of their lines heparin-coated?' A patient with no documented heparin orders may still have significant heparin exposure from flushes, particularly in the ICU or during procedures (cardiac catheterization, hemodialysis). Document all sources of heparin exposure clearly, as this impacts both the 4T score and the clinical management (all heparin products must be stopped in suspected HIT, including flushes—switch to normal saline flushes).
Despite the name 'thrombocytopenia' and low platelet counts, HIT is a PROTHROMBOTIC disorder, not a bleeding disorder. The pathophysiology involves anti-PF4/heparin antibodies activating platelets, leading to platelet consumption (causing thrombocytopenia) and massive thrombin generation (causing thrombosis). Up to 50% of patients with HIT develop thrombosis (HITT = HIT with Thrombosis), including DVT, PE, arterial thrombosis (limb ischemia, stroke, MI), and unusual sites (adrenal vein thrombosis, cerebral sinus thrombosis). Bleeding in HIT is RARE unless platelets drop to extreme levels (<10–20K) or the patient has concurrent coagulopathy. When scoring the 'Thrombosis' component, actively look for thrombosis even if the patient is asymptomatic: order bilateral lower extremity Dopplers in high-probability HIT to screen for occult DVT. New thrombosis in a patient with thrombocytopenia on heparin is HIT until proven otherwise. Remember: platelets dropping + new clot = think HIT, not DIC.
One of the most important diagnostic clues for HIT is that the platelet nadir is usually in the range of 50,000–150,000/μL (median ~60K). HIT rarely causes profound thrombocytopenia (<20,000/μL). If a patient's platelets drop to <10–20K, strongly consider alternative etiologies: immune thrombocytopenia (ITP), drug-induced thrombocytopenia (vancomycin, linezolid, valproic acid), DIC, TTP/HUS, sepsis, or bone marrow suppression. This is reflected in the 4T score 'Thrombocytopenia' component: platelet nadir <10K scores 0 points (inconsistent with HIT). However, the percent drop from baseline is more important than the absolute nadir—a patient with baseline platelets of 400K dropping to 150K (a >60% fall) may still have HIT even though 150K is not severely low. Always calculate the percentage drop from the pre-heparin baseline, not from the hospital admission baseline (which may already reflect early HIT-related drop).
The intermediate-probability category (4T score 4–5) presents the greatest clinical challenge because ~14% of these patients have HIT (meaning ~86% do not), yet guidelines recommend stopping heparin and starting alternative anticoagulation while awaiting HIT antibody results. This approach prevents thrombosis in the true HIT patients but exposes many non-HIT patients to unnecessary risks and costs of alternative anticoagulants (argatroban carries bleeding risk and requires aPTT monitoring every 2–4 hours; bivalirudin can be difficult to dose in renal insufficiency). In intermediate-probability patients, apply additional clinical judgment: If the clinical picture is highly suspicious despite a score of 4–5 (e.g., classic 5–10 day timing, >50% platelet drop, new DVT, no other clear cause), treat empirically for HIT. If the picture is less convincing (e.g., septic patient with multiple potential causes of thrombocytopenia, platelet drop only 35%, no thrombosis), consider rapid HIT ELISA if available (results in 4–6 hours at some centers) before committing to alternative anticoagulation. Some institutions use a modified threshold (4T ≥6 for empiric treatment) to reduce overtreatment, though this is not guideline-endorsed.
In high-probability HIT (4T score 6–8), the risk of thrombosis is so significant (~64% have HIT, and among HIT patients ~50% develop thrombosis) that you must act immediately without waiting for laboratory confirmation. Step 1: STOP all heparin products—subcutaneous prophylaxis, IV heparin infusions, heparin flushes, heparin-coated catheters (replace with non-heparin-coated lines), dialysis circuits using heparin anticoagulation. Step 2: START alternative anticoagulation with a direct thrombin inhibitor (argatroban preferred in liver dysfunction, bivalirudin in renal dysfunction) or fondaparinux. Do NOT start warfarin acutely (warfarin depletes protein C before factors II/X, causing transient hypercoagulability and venous limb gangrene in HIT—warfarin should only be started after platelets recover to >150K and overlapped with a direct thrombin inhibitor for 5 days). Step 3: SEND HIT antibody testing (ELISA and confirmatory SRA/HIPA). Step 4: SCREEN for thrombosis with bilateral LE Dopplers. Time is critical—delaying alternative anticoagulation by even 24 hours while waiting for lab results can result in catastrophic thrombosis (stroke, limb loss, death).
Patients with a history of HIT who are re-exposed to heparin (even months or years later) can develop rapid-onset HIT, with platelet drop occurring within hours to 1 day of re-exposure rather than the typical 5–10 days. This occurs because circulating anti-PF4/heparin antibodies persist for weeks to months after the initial HIT episode (though they eventually wane). Rapid-onset HIT scores 2 points for the 'Timing' component if heparin exposure occurred within the past 30 days, or 1 point if exposure was 31–100 days ago. Clinically, this means: (1) Always take a careful heparin exposure history—ask 'Have you ever been told you had a reaction to heparin or had low platelets while on a blood thinner?' (2) If a patient has documented prior HIT, AVOID all heparin products indefinitely (use fondaparinux, direct oral anticoagulants, or bivalirudin for anticoagulation needs). (3) If heparin exposure is unavoidable (e.g., urgent cardiac surgery requiring cardiopulmonary bypass), pre-treat with plasmapheresis or IV immunoglobulin to remove antibodies, and use short-duration heparin only during bypass (transition immediately to non-heparin anticoagulation post-op). Document HIT history prominently in the medical record and consider a medical alert bracelet.
HIT antibody testing typically uses an immunoassay (ELISA) to detect anti-PF4/heparin IgG antibodies, reported as an optical density (OD) value. The OD value correlates with the likelihood of true HIT (confirmed by functional assays like serotonin release assay). **OD <0.4:** Negative—HIT is excluded. **OD 0.4–1.0:** Weakly positive—most are false positives, especially in low 4T score patients; functional assay (SRA) is often negative. **OD 1.0–2.0:** Moderately positive—about 50% are true HIT; functional assay recommended. **OD >2.0:** Strongly positive—>90% are true HIT; functional assay usually positive. Integrate the OD value with the 4T score: a high 4T score (6–8) + high OD (>2.0) has >95% positive predictive value for HIT—you can confidently diagnose HIT and continue alternative anticoagulation. A low 4T score (0–3) + low OD (<1.0) essentially excludes HIT—stop alternative anticoagulation and resume heparin if needed. In discordant cases (low 4T + high OD, or high 4T + low OD), send confirmatory SRA and use clinical judgment, as one of the assessments (clinical or laboratory) is likely incorrect.
In HIT, platelet transfusions are contraindicated except in cases of life-threatening bleeding (e.g., intracranial hemorrhage, massive GI bleed with hemodynamic instability). The rationale: HIT is a prothrombotic state driven by platelet activation, and transfusing additional platelets can paradoxically worsen thrombosis by providing more substrate for antibody-mediated activation. Multiple case reports and case series have documented new or worsening thrombosis (DVT, PE, limb ischemia, stroke) immediately following platelet transfusion in HIT patients. Most HIT patients have platelet counts in the 50,000–150,000/μL range, which is sufficient for hemostasis in most scenarios (even procedures like central line placement can be performed safely at platelet counts >50K). If a HIT patient requires an invasive procedure and platelets are <50K, consider delaying the procedure until platelets recover on alternative anticoagulation, or use local hemostatic measures rather than platelet transfusion. Document clearly in the chart: 'HIT suspected/confirmed—avoid platelet transfusion unless life-threatening bleeding.' Educate nursing and pharmacy to flag platelet orders in HIT patients.
HIT is one of many causes of thrombocytopenia in hospitalized patients. The differential diagnosis includes: **Sepsis/DIC:** Low platelets, elevated PT/aPTT, low fibrinogen, elevated D-dimer, schistocytes on smear. **Drug-induced thrombocytopenia:** Common culprits include vancomycin (occurs in ~20% of patients, usually after 7–10 days), linezolid, valproate, quinine, GPIIb/IIIa inhibitors. Unlike HIT, these do not cause thrombosis. **Immune thrombocytopenia (ITP):** Isolated thrombocytopenia with normal/elevated megakaryocytes on bone marrow, no associated thrombosis, responds to IVIG/steroids. **TTP/HUS:** Severe thrombocytopenia (<20K), microangiopathic hemolytic anemia (schistocytes, low haptoglobin), AKI, neurologic changes, fever (pentad). **Dilutional/consumptive:** Post-massive transfusion, post-cardiopulmonary bypass. **Heparin effect (non-immune):** HIT Type I—transient, mild platelet drop (10–20%) within 1–4 days, no clinical significance, platelets recover despite continued heparin. The 4T score helps differentiate HIT from these alternatives by systematically scoring timing, thrombosis, and other causes. A patient with profound thrombocytopenia (<10K), prolonged PT/aPTT, low fibrinogen, and multiorgan failure likely has DIC (4T score would be low due to definite other cause). A patient with isolated moderate thrombocytopenia, 5–10 day timing, and new DVT on heparin likely has HIT (4T score would be high).
Your 4T score estimates the pretest probability of heparin-induced thrombocytopenia (HIT). A score of 0–3 indicates low probability, with only about 5% of patients in this range actually having HIT — the negative predictive value exceeds 99%, making it an excellent rule-out tool. A score of 4–5 indicates intermediate probability (~14% chance of HIT), warranting further laboratory evaluation. A score of 6–8 indicates high probability (~64% chance of HIT), requiring immediate clinical action.
The 4T score is most valuable at the low end: a low score can confidently exclude HIT and avoid unnecessary discontinuation of heparin and costly laboratory testing. However, intermediate and high scores cannot confirm HIT — they indicate the need for immunoassay (HIT ELISA) and functional assay (serotonin release assay) for definitive diagnosis.
Use the 4T score whenever HIT is suspected in a patient receiving or recently exposed to heparin who develops a new or worsening thrombocytopenia (platelet count drop >30–50% from baseline). It should be the first step in the diagnostic workup, applied before ordering HIT antibody testing, as it can efficiently rule out HIT in low-probability cases and prevent unnecessary testing and treatment changes.
The 4T score is particularly important because the clinical consequences of both missing HIT (life-threatening thrombosis) and overdiagnosing HIT (unnecessary alternative anticoagulation, which is more expensive and carries its own bleeding risks) are significant. It is recommended by the American Society of Hematology (ASH) guidelines as the initial assessment tool for suspected HIT.
The 4T score has significant inter-observer variability, particularly in assessing the 'Timing' and 'oTher causes' categories. Studies have shown only moderate agreement between clinicians scoring the same patient, which can shift a patient between risk categories. The score performs best in medical and surgical populations but has lower specificity in critically ill or postoperative patients, where thrombocytopenia has many competing causes (sepsis, DIC, drug-induced, dilutional).
The intermediate probability category (score 4–5) is problematic because it includes a large proportion of patients who do not have HIT, yet clinical practice often requires presumptive treatment (heparin cessation and alternative anticoagulation) while awaiting laboratory confirmation. The 4T score also does not differentiate between the clinically benign HIT type I (non-immune, transient platelet drop) and the dangerous immune-mediated HIT type II. Finally, the score was not designed for patients with delayed-onset HIT (occurring after heparin discontinuation) or autoimmune HIT.
For related assessments, see Wells Score (DVT), Wells Score (PE) and HAS-BLED Score.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
Calculate the Wells Score to assess the clinical probability of deep vein thrombosis (DVT). Guide diagnostic workup and D-dimer testing.
EmergencyCalculate the Wells Score to estimate the clinical probability of pulmonary embolism (PE). Guide decisions on CTPA and D-dimer testing.
CardiologyCalculate the HAS-BLED score to assess bleeding risk in patients on anticoagulation therapy. Balance stroke prevention against bleeding risk.